This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Clinical trial NCT07520318 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07520318
- Sponsor
- Shenzhen Oculgen Biomedical Technology Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-17
- Primary completion
- 2029-02-01
- Enrollment
- 255
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.